X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2497) 2497
male (1739) 1739
female (1738) 1738
middle aged (1520) 1520
oncology (1442) 1442
adult (1433) 1433
aged (1230) 1230
dacarbazine - administration & dosage (1212) 1212
dacarbazine - adverse effects (1173) 1173
dacarbazine - analogs & derivatives (1151) 1151
antineoplastic combined chemotherapy protocols - therapeutic use (993) 993
chemotherapy (942) 942
dacarbazine - therapeutic use (891) 891
antineoplastic combined chemotherapy protocols - adverse effects (793) 793
temozolomide (791) 791
treatment outcome (713) 713
cancer (621) 621
melanoma - drug therapy (614) 614
dacarbazine (571) 571
brain neoplasms - drug therapy (534) 534
antineoplastic agents, alkylating - therapeutic use (477) 477
radiotherapy (470) 470
antineoplastic agents, alkylating - adverse effects (457) 457
adolescent (456) 456
disease-free survival (452) 452
melanoma (444) 444
combined modality therapy (412) 412
doxorubicin - administration & dosage (404) 404
hodgkin disease - drug therapy (388) 388
care and treatment (349) 349
glioblastoma - drug therapy (347) 347
glioblastoma (346) 346
survival (328) 328
medicine & public health (325) 325
antineoplastic combined chemotherapy protocols - administration & dosage (316) 316
bleomycin - administration & dosage (310) 310
doxorubicin - adverse effects (310) 310
aged, 80 and over (303) 303
young adult (298) 298
prognosis (293) 293
clinical neurology (291) 291
vincristine - administration & dosage (291) 291
drug administration schedule (290) 290
retrospective studies (289) 289
skin neoplasms - drug therapy (289) 289
survival analysis (281) 281
neoplasm staging (276) 276
trial (275) 275
therapy (272) 272
vinblastine - administration & dosage (268) 268
bleomycin - adverse effects (253) 253
survival rate (253) 253
antineoplastic agents, alkylating - administration & dosage (249) 249
metastatic melanoma (246) 246
melanoma - pathology (231) 231
follow-up studies (228) 228
gliomas (228) 228
glioma - drug therapy (223) 223
glioblastoma multiforme (220) 220
antineoplastic agents - therapeutic use (218) 218
antineoplastic agents - adverse effects (213) 213
hematology (211) 211
melanoma - secondary (210) 210
vinblastine - adverse effects (208) 208
brain neoplasms - pathology (204) 204
brain neoplasms - radiotherapy (202) 202
tumors (200) 200
malignant glioma (196) 196
toxicity (194) 194
brain neoplasms - mortality (191) 191
vinblastine (190) 190
vincristine - adverse effects (188) 188
clinical trials (187) 187
phase-ii (185) 185
kaplan-meier estimate (184) 184
metastasis (183) 183
skin neoplasms - pathology (183) 183
brain neoplasms - therapy (181) 181
disease progression (181) 181
immunotherapy (178) 178
child (175) 175
antineoplastic agents (174) 174
procarbazine - administration & dosage (174) 174
drug therapy (172) 172
pharmacology & pharmacy (170) 170
radiation-therapy (170) 170
neoplasm metastasis (169) 169
animals (167) 167
research (166) 166
glioblastoma - radiotherapy (164) 164
prednisone - administration & dosage (164) 164
analysis (163) 163
adjuvant temozolomide (161) 161
malignant-melanoma (161) 161
cyclophosphamide - administration & dosage (160) 160
cisplatin - administration & dosage (157) 157
disease (156) 156
patients (156) 156
phase-ii trial (156) 156
antimitotic agents (154) 154
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2527) 2527
German (40) 40
French (35) 35
Chinese (16) 16
Spanish (16) 16
Japanese (14) 14
Russian (14) 14
Polish (10) 10
Czech (3) 3
Hebrew (3) 3
Hungarian (3) 3
Italian (3) 3
Norwegian (3) 3
Bulgarian (2) 2
Dutch (2) 2
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2011, Volume 365, Issue 3, pp. 203 - 212
.... BEACOPP therapy was associated with higher initial rates of complete response and freedom from relapse but also with more short-term and long-term toxic effects... 
CELL TRANSPLANT | MEDICINE, GENERAL & INTERNAL | VINORELBINE | MOPP | DISEASE | REGIMEN | IFOSFAMIDE | CHEMOTHERAPY | STANDARD | HYBRID | FERTILITY | Doxorubicin - therapeutic use | Dacarbazine - adverse effects | Dacarbazine - therapeutic use | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vinblastine - therapeutic use | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Young Adult | Hodgkin Disease - radiotherapy | Bleomycin - therapeutic use | Vinblastine - adverse effects | Hodgkin Disease - drug therapy | Hodgkin Disease - mortality | Adult | Female | Etoposide - adverse effects | Prednisone - adverse effects | Kaplan-Meier Estimate | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Etoposide - therapeutic use | Combined Modality Therapy | Bleomycin - adverse effects | Remission Induction | Disease-Free Survival | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Hodgkin Disease - therapy | Adolescent | Vincristine - therapeutic use | Vincristine - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Prednisone - therapeutic use | Procarbazine | Vinblastine | Disease | Etoposide | Prednisone | Family medical history | Radiation therapy | Patients | Lymphoma | Doxorubicin | Survival | Vincristine | Studies | Hepatitis | Dacarbazine | Cyclophosphamide | Chemotherapy | Bleomycin | Tomography | Lymphomas | Hodgkin's disease
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2013, Volume 31, Issue 5, pp. 592 - 598
Purpose To assess therapy-related acute myeloid leukemia/myelodysplastic syndrome (t-AML/MDS) risk in patients treated for Hodgkin lymphoma (HL) on successive... 
2ND CANCER-RISK | RANDOMIZED-TRIALS | ONCOLOGY | DNA TOPOISOMERASE-II | ALKYLATING-AGENTS | COMBINED-MODALITY TREATMENT | DISEASE | MYELOID-LEUKEMIA | MYELODYSPLASTIC SYNDROMES | CHEMOTHERAPY | ACUTE PROMYELOCYTIC LEUKEMIA | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Hodgkin Disease - pathology | Humans | Leukemia, Myeloid, Acute - epidemiology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Mechlorethamine - adverse effects | Male | Risk | Leukemia, Myeloid, Acute - etiology | Incidence | Hodgkin Disease - radiotherapy | Melphalan - adverse effects | Chemotherapy, Adjuvant - adverse effects | Radiotherapy, Adjuvant - adverse effects | Vinblastine - adverse effects | Hodgkin Disease - drug therapy | Adult | Female | Retrospective Studies | Databases, Factual | Radiotherapy Dosage | Prednisone - adverse effects | Drug Administration Schedule | California - epidemiology | Clinical Trials as Topic | Bleomycin - adverse effects | Academic Medical Centers | Myelodysplastic Syndromes - epidemiology | Myelodysplastic Syndromes - etiology | Neoplasms, Second Primary - epidemiology | Neoplasms, Second Primary - etiology | Methotrexate - adverse effects | Procarbazine - adverse effects | Vincristine - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Hema14 | Hema13 | Hema12 | ORIGINAL REPORTS
Journal Article
Nature Reviews Clinical Oncology, ISSN 1759-4774, 10/2009, Volume 6, Issue 10, pp. 596 - 603
...REVIEWS Neurological adverse effects caused by cytotoxic and targeted therapies David Schiff, Patrick Y. Wen and Martin J. van den Bent Abstract | Historically... 
PHASE-II TRIAL | ONCOLOGY | POSTERIOR LEUKOENCEPHALOPATHY SYNDROME | ALBUMIN-BOUND PACLITAXEL | BRAIN-TUMOR CONSORTIUM | ACUTE TRANSIENT ENCEPHALOPATHY | CEREBROSPINAL-FLUID PHARMACOKINETICS | OXALIPLATIN-RELATED NEUROTOXICITY | RECURRENT MALIGNANT GLIOMAS | ANALOG IXABEPILONE BMS-247550 | ADVANCED COLORECTAL-CANCER | Dacarbazine - adverse effects | United States | Humans | Antibodies, Monoclonal - adverse effects | Boronic Acids - adverse effects | Drug Approval | Epothilones - adverse effects | Bevacizumab | Antibodies, Monoclonal, Humanized | Antineoplastic Agents - adverse effects | Dacarbazine - analogs & derivatives | Pyrroles - adverse effects | Angiogenesis Inhibitors - adverse effects | United States Food and Drug Administration | Tubulin Modulators - adverse effects | Bortezomib | Clinical Trials as Topic | Imatinib Mesylate | Piperazines - adverse effects | Neoplasms - drug therapy | Neurotoxicity Syndromes - etiology | Indoles - adverse effects | Pyrazines - adverse effects | Pyrimidines - adverse effects | Benzamides | Antineoplastic Agents, Alkylating - adverse effects | Organoplatinum Compounds - adverse effects | Antimitotic agents | Complications and side effects | Nervous system diseases | Patient outcomes | Dosage and administration | Genetic aspects | Research | Antineoplastic agents | Drug therapy | Risk factors | Cancer | Index Medicus
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2013, Volume 31, Issue 2, pp. 231 - 239
Purpose To optimize fertility advice in patients with Hodgkin lymphoma (HL) before therapy and during survivorship, information on the impact of chemotherapy... 
INHIBIN-B | PRESERVATION | OUTCOME MEASURE | OVARIAN RESERVE | ONCOLOGY | TERM FOLLOW-UP | DISEASE | FEMALE CANCER SURVIVORS | ANTI-MULLERIAN HORMONE | CHEMOTHERAPY | SERUM MARKER | Procarbazine - administration & dosage | Cyclophosphamide - administration & dosage | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vinblastine - administration & dosage | Cyclophosphamide - adverse effects | Gonadotropin-Releasing Hormone - analogs & derivatives | Fertility - physiology | Fertility Preservation | Young Adult | Vinblastine - adverse effects | Follicle Stimulating Hormone - blood | Hodgkin Disease - drug therapy | Oligospermia - epidemiology | Vincristine - administration & dosage | Adult | Female | Gonadotropin-Releasing Hormone - therapeutic use | Hodgkin Disease - physiopathology | Inhibins - blood | Menstrual Cycle - drug effects | Testosterone - blood | Menstrual Cycle - physiology | Doxorubicin - administration & dosage | Dacarbazine - administration & dosage | Prednisone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Survivors | Etoposide - administration & dosage | Ovary - physiology | Hodgkin Disease - epidemiology | Bleomycin - administration & dosage | Bleomycin - adverse effects | Germany - epidemiology | Randomized Controlled Trials as Topic | Pregnancy | Testis - physiology | Hodgkin Disease - blood | Procarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - adverse effects | Doxorubicin - adverse effects | Index Medicus
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2013, Volume 31, Issue 6, pp. 684 - 691
Journal Article
Fertility and Sterility, ISSN 0015-0282, 2014, Volume 102, Issue 3, pp. 667 - 674.e3
Objective To determine consequences of lymphoma treatments on sperm characteristics and sperm DNA, and to evaluate predictors of sperm recovery. Design... 
Internal Medicine | Obstetrics and Gynecology | sperm DNA | sperm chromatin | radiotherapy | spermatogenesis | Hodgkin | Lymphoma | chemotherapy | DNA INTEGRITY | FERTILITY PRESERVATION | CHROMATIN-STRUCTURE | TESTICULAR CANCER | CRYOPRESERVATION | SEMEN QUALITY | OBSTETRICS & GYNECOLOGY | REPRODUCTIVE BIOLOGY | HODGKINS-DISEASE | MEN | GONADAL DYSFUNCTION | Doxorubicin - therapeutic use | Sperm Count | Dacarbazine - adverse effects | Dacarbazine - therapeutic use | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Mechlorethamine - adverse effects | Male | Vinblastine - therapeutic use | Cyclophosphamide - adverse effects | DNA - radiation effects | Mechlorethamine - therapeutic use | Case-Control Studies | Cyclophosphamide - therapeutic use | Young Adult | Bleomycin - therapeutic use | Vinblastine - adverse effects | Adult | DNA - drug effects | Spermatogenesis - radiation effects | Spermatogenesis - drug effects | Prednisone - adverse effects | Spermatozoa - radiation effects | Semen Analysis | Combined Modality Therapy | Bleomycin - adverse effects | Spermatozoa - drug effects | DNA - chemistry | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, Non-Hodgkin - therapy | Hodgkin Disease - therapy | Vincristine - therapeutic use | Vincristine - adverse effects | Spermatozoa - physiology | DNA Damage | Longitudinal Studies | Doxorubicin - adverse effects | Prednisone - therapeutic use | Care and treatment | Spermatozoa | Lymphomas | Drug therapy | DNA | Cancer
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2012, Volume 30, Issue 33, pp. 4117 - 4123
Purpose Although the outcome of patients with HIV-related Hodgkin lymphoma (HIV-HL) has markedly improved since the introduction of combined antiretroviral... 
SURVIVAL | PROGNOSTIC-FACTORS | ONCOLOGY | ACTIVE ANTIRETROVIRAL THERAPY | DISEASE | STANFORD-V | RADIOTHERAPY | STEM-CELL TRANSPLANTATION | PATIENTS PTS | IMMUNODEFICIENCY | CHEMOTHERAPY | Procarbazine - administration & dosage | Cyclophosphamide - administration & dosage | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Prospective Studies | Hodgkin Disease - pathology | Humans | Lymphoma, AIDS-Related - pathology | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vinblastine - administration & dosage | Cyclophosphamide - adverse effects | Young Adult | Hodgkin Disease - radiotherapy | Vinblastine - adverse effects | Hodgkin Disease - drug therapy | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Lymphoma, AIDS-Related - drug therapy | Dacarbazine - administration & dosage | Prednisone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Etoposide - administration & dosage | Treatment Outcome | Combined Modality Therapy | Bleomycin - administration & dosage | Bleomycin - adverse effects | Remission Induction | Disease-Free Survival | Procarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | HIV Infections - complications | Lymphoma, AIDS-Related - radiotherapy | Vincristine - adverse effects | Aged | Neoplasm Staging | Doxorubicin - adverse effects
Journal Article
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2009, Volume 27, Issue 35, pp. 5874 - 5880
Purpose The standard of care for anaplastic gliomas is surgery followed by radiotherapy. The NOA-04 phase III trial compared efficacy and safety of... 
MALIGNANT GLIOMA | SURVIVAL | ONCOLOGY | GLIOBLASTOMA-MULTIFORME | EUROPEAN ORGANIZATION | MGMT GENE | OLIGODENDROGLIAL TUMORS | RADIOTHERAPY | CHEMOTHERAPY | BRAIN-TUMORS | 1P/19Q LOSS | Procarbazine - administration & dosage | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Lomustine - adverse effects | Middle Aged | Brain Neoplasms - pathology | DNA Repair Enzymes - genetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents, Alkylating - administration & dosage | Glioma - radiotherapy | Glioma - genetics | Young Adult | DNA Methylation | Time Factors | Radiotherapy, Adjuvant - adverse effects | Glioma - pathology | Treatment Failure | Tumor Suppressor Proteins - genetics | Dacarbazine - analogs & derivatives | Vincristine - administration & dosage | Adult | Female | Brain Neoplasms - mortality | Chemotherapy, Adjuvant | Brain Neoplasms - radiotherapy | Promoter Regions, Genetic | Dacarbazine - administration & dosage | Glioma - mortality | Drug Administration Schedule | Risk Assessment | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Brain Neoplasms - genetics | Isocitrate Dehydrogenase - genetics | Brain Neoplasms - drug therapy | Disease Progression | Disease-Free Survival | DNA Modification Methylases - genetics | Procarbazine - adverse effects | Vincristine - adverse effects | Aged | Mutation | Antineoplastic Agents, Alkylating - adverse effects | Lomustine - administration & dosage | Glioma - drug therapy | Index Medicus
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2018, Volume 36, Issue 4, pp. 383 - 390
Journal Article
American Journal of Medicine, The, ISSN 0002-9343, 2014, Volume 127, Issue 10, pp. 931 - 932
Internal Medicine | MEDICINE, GENERAL & INTERNAL | STEVENS-JOHNSON-SYNDROME | Acetaminophen - adverse effects | Dacarbazine - adverse effects | Methylprednisolone - therapeutic use | Humans | Middle Aged | Dexamethasone - adverse effects | Male | Antineoplastic Agents - therapeutic use | Wound Healing | Anticonvulsants - adverse effects | Piracetam - therapeutic use | Stevens-Johnson Syndrome - therapy | Anti-Inflammatory Agents - therapeutic use | Anti-Inflammatory Agents - administration & dosage | Antiemetics - adverse effects | Oxycodone - therapeutic use | Stevens-Johnson Syndrome - etiology | Anticonvulsants - therapeutic use | gamma-Globulins - therapeutic use | Analgesics, Opioid - therapeutic use | Stevens-Johnson Syndrome - diagnosis | Dexamethasone - therapeutic use | Glioblastoma - pathology | Piracetam - analogs & derivatives | Glioblastoma - complications | Glioblastoma - drug therapy | gamma-Globulins - administration & dosage | Dacarbazine - therapeutic use | Piracetam - adverse effects | Erythema - chemically induced | Analgesics, Opioid - adverse effects | Antineoplastic Agents - adverse effects | Antiemetics - therapeutic use | Erythema - diagnosis | Dacarbazine - analogs & derivatives | Oxycodone - adverse effects | Acetaminophen - therapeutic use | Proton Pump Inhibitors - adverse effects | Omeprazole - therapeutic use | Immunologic Factors - administration & dosage | Omeprazole - adverse effects | Proton Pump Inhibitors - therapeutic use | Piperidines - therapeutic use | Quinazolines - therapeutic use | Piperidines - adverse effects | Quinazolines - adverse effects | Drug Combinations | Immunologic Factors - therapeutic use | Methylprednisolone - administration & dosage | Medicine, Experimental | Toxic epidermal necrolysis | Medical research | Research
Journal Article